Over 80% of pharmaceutircals are purchased through a PBM

PBM's negotiate on behalf of insuranec to "get the best deal" but are still for profit companies. They profit as a percetage per perscriptions, which means they are likely to encourage use of brands that get higher rebates (discounts from manufacturers) instead of cheapest or more effective They often take a large cut by charging more than they reimburse pharmacies, and keep the difference.



[http://www.pbmwatch.com/the-pbm-problem.html#:~:text=Although%20the%20primary%20function%20of,ultimately%20increased%20the%20cost%20of](http://www.pbmwatch.com/the-pbm-problem.html#:~:text=Although%20the%20primary%20function%20of,ultimately%20increased%20the%20cost%20of)

The U.S. pharmacy benefit management market size was valued at USD **368.3 billion** in 2018. It is expected to expand at a **CAGR of 9.2% over the forecast period**. Increase in healthcare expenditure has played a pivotal role in the development of the market.

PBM growth is estimated to continuously outpace inflation in terms of growth, and is about 60% of the pharma market, with total spending of medicine at 539 billion